• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

TAK-632

Product ID T0140
Cas No. 1228591-30-7
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $95.50 In stock
5 mg $176.30 In stock
10 mg $267.90 In stock
25 mg $558.80 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

TAK 632 is a benzothiazole pan-Raf inhibitor that displays anticancer chemotherapeutic activity. TAK 632 induces dimerization of Raf but prevents kinase activity. This compound inhibits cellular proliferation of melanoma cells and inhibits tumor growth in animal models of melanoma.

Product Info

Cas No.

1228591-30-7

Purity

≥99%

Formula

C27H18F4N4O3S

Formula Wt.

554.52

IUPAC Name

N-{7-Cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide

Synonym

TAK632

Solubility

DMSO 100 mg/mL (180.33 mM) Ethanol 2 mg/mL (3.6 mM) Water Insoluble

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

T0140 MSDS PDF

Info Sheet

T0140 Info Sheet PDF

References

Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013 Dec 1;73(23):7043-55. PMID: 24121489.

Okaniwa M, Hirose M, Arita T, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013 Aug 22;56(16):6478-94. PMID: 23906342.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only